“…Knowledge of the pharmacology of cardiac glycosides such as oleandrin derived exclusively from Nerium oleander , however, has expanded greatly over the last 20 years ( Newman et al., 2008 ; Riganti et al., 2011 ). For example, proposed anti-proliferative mechanisms of oleandrin have included reports of altered membrane fluidity ( Manna et al., 2006 ), decreased activation of Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), c-Jun N-terminal kinase (JNK) and activator protein 1 (AP-1) ( Manna et al., 2000 ), increased cellular calcium ( McConkey et al., 2000 ), inhibition of the Signal transducer and activator of transcription 3 (STAT-3) signaling pathway ( Ko et al., 2018 ), decreased phosphorylation of Protein kinase B (Akt) ( Afaq et al., 2004 ), decreased cellular transport of basic fibroblast growth factor 2 (FGF-2) ( Smith et al., 2001 ), initiation of Apo2 ligand/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) apoptosis via increased expression of death receptors 4 and 5 ( Frese et al., 2006 ), induction of immunogenic cell death ( Menger et al., 2012 ; Diederich et al., 2017 ), and inhibition of components of the mammalian target of rapamycin (mTOR) pathway ( Schoner and Scheiner-Bobis, 2007 ) to name but a few. In addition, our research and that of others have shown a strong ability of oleandrin to induce the synthesis of brain derived neurotrophic factor (BDNF), which may be essential to augmentation of normal brain health ( Van Kanegan et al., 2014 ; Garofalo et al., 2017 ).…”